In this educational Medication Review, Claudia Rivera-Salas, DNP, provides a practical overview of deucravacitinib and its role in the treatment of immune-mediated diseases such as psoriatic arthritis and plaque psoriasis. This video highlights why deucravacitinib, a selective TYK2 inhibitor, is gaining attention for its unique mechanism of action and ease of use in clinical practice.

Learn how deucravacitinib stands out as a once-daily oral therapy with a fixed dose—requiring no titration, no routine dose adjustments, and the flexibility to be taken with or without food, helping to support patient adherence. Claudia explains how its targeted inhibition of the TYK2 regulatory domain differentiates it from traditional JAK inhibitors, contributing to a favorable safety profile without boxed warnings for major adverse cardiovascular events (MACE), venous thromboembolism (VTE), malignancy, or serious infections observed in clinical trials.

The discussion also covers key clinical considerations, including minimal drug-drug interactions, the lack of required routine lab monitoring, and important precautions for patients with severe hepatic impairment or those who are pregnant or breastfeeding. Currently approved for adults with moderate to severe plaque psoriasis and psoriatic arthritis, deucravacitinib is also being investigated across a range of autoimmune conditions.

Watch this video to understand how deucravacitinib fits into modern rheumatology and dermatology treatment strategies, and why its balance of efficacy, safety, and convenience makes it a valuable option for both providers and patients managing chronic inflammatory diseases. For more rheumatology resources, visit the RhAPP Content Rheum, RhAPP ACE app, or follow RhAPP on Instagram, LinkedIn, or Facebook.